RPRX Royalty Pharma plc
Price (delayed)
$32.03
Market cap
$18.46B
P/E Ratio
16.68
Dividend/share
$0.85
EPS
$1.92
Enterprise value
$25.15B
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals
Highlights
RPRX's equity is up by 2.6% year-on-year
The P/E is 64% lower than the 5-year quarterly average of 46.5 but 12% higher than the last 4 quarters average of 14.7
The company's quick ratio has shrunk by 82% YoY and by 7% QoQ
Royalty Pharma's EPS has decreased by 25% QoQ and by 24% YoY
Key stats
What are the main financial stats of RPRX
Market
Valuations
Earnings
Shares outstanding
576.45M
Market cap
$18.46B
Enterprise value
$25.15B
Price to earnings (P/E)
16.68
Price to book (P/B)
1.82
Price to sales (P/S)
6.34
EV/EBIT
23.19
EV/EBITDA
23.19
EV/Sales
11.11
Revenue
$2.26B
Gross profit
$2.26B
Operating income
$1.29B
Net income
$858.98M
EBIT
$1.08B
EBITDA
$1.08B
Free cash flow
$2.69B
Per share
Balance sheet
Liquidity
EPS
$1.92
EPS diluted
$1.91
Free cash flow per share
$6.01
Book value per share
$17.55
Revenue per share
$5.05
TBVPS
$40.66
Total assets
$18.22B
Total liabilities
$7.88B
Debt
$7.61B
Equity
$10.34B
Working capital
$548.52M
Debt to equity
0.74
Current ratio
1.44
Quick ratio
1.43
Net debt/EBITDA
6.16
Margins
Efficiency
Dividend
EBITDA margin
47.9%
Gross margin
100%
Net margin
37.9%
Operating margin
57.1%
Return on assets
4.9%
Return on equity
8.5%
Return on invested capital
4.7%
Return on capital employed
6.4%
Return on sales
47.9%
Dividend yield
2.65%
DPS
$0.85
Payout ratio
44.3%
RPRX stock price
How has the Royalty Pharma stock price performed over time
Intraday
1.07%
1 week
-1.75%
1 month
-5.1%
1 year
14.47%
YTD
25.56%
QTD
2.89%
Financial performance
How have Royalty Pharma's revenue and profit performed over time
Revenue
$2.26B
Gross profit
$2.26B
Operating income
$1.29B
Net income
$858.98M
Gross margin
100%
Net margin
37.9%
Royalty Pharma's net margin has decreased by 25% QoQ and by 21% YoY
The net income has contracted by 25% from the previous quarter and by 24% YoY
The operating income has contracted by 16% from the previous quarter and by 13% YoY
The operating margin has declined by 16% since the previous quarter and by 10% year-on-year
Growth
What is Royalty Pharma's growth rate over time
Valuation
What is Royalty Pharma stock price valuation
P/E
16.68
P/B
1.82
P/S
6.34
EV/EBIT
23.19
EV/EBITDA
23.19
EV/Sales
11.11
The P/E is 64% lower than the 5-year quarterly average of 46.5 but 12% higher than the last 4 quarters average of 14.7
Royalty Pharma's EPS has decreased by 25% QoQ and by 24% YoY
RPRX's P/B is 30% below its 5-year quarterly average of 2.6 but 13% above its last 4 quarters average of 1.6
RPRX's equity is up by 2.6% year-on-year
The P/S is 14% above the last 4 quarters average of 5.5 but 9% below the 5-year quarterly average of 6.9
The revenue has decreased by 3.9% YoY
Efficiency
How efficient is Royalty Pharma business performance
The ROA has decreased by 28% YoY and by 27% from the previous quarter
RPRX's ROE is down by 26% from the previous quarter and by 26% YoY
The ROIC is down by 24% YoY and by 22% QoQ
Royalty Pharma's return on sales has decreased by 20% QoQ and by 15% YoY
Dividends
What is RPRX's dividend history
DPS
$0.85
Dividend yield
2.65%
Payout ratio
44.3%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Royalty Pharma financials performed over time
Royalty Pharma's total assets is 131% more than its total liabilities
The current ratio has dropped by 82% year-on-year and by 6% since the previous quarter
The company's quick ratio has shrunk by 82% YoY and by 7% QoQ
Royalty Pharma's debt is 26% lower than its equity
Royalty Pharma's debt has increased by 24% YoY
The debt to equity has increased by 21% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.